GB2034718A - Prolylphenylalanylarginine Derivatives, Process for Their Preparation and Their Use for Measuring Enzyme Activity - Google Patents

Prolylphenylalanylarginine Derivatives, Process for Their Preparation and Their Use for Measuring Enzyme Activity Download PDF

Info

Publication number
GB2034718A
GB2034718A GB7937424A GB7937424A GB2034718A GB 2034718 A GB2034718 A GB 2034718A GB 7937424 A GB7937424 A GB 7937424A GB 7937424 A GB7937424 A GB 7937424A GB 2034718 A GB2034718 A GB 2034718A
Authority
GB
United Kingdom
Prior art keywords
enzyme
naphthyl
arginine
benzoyl
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7937424A
Other versions
GB2034718B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torii and Co Ltd
Original Assignee
Torii and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torii and Co Ltd filed Critical Torii and Co Ltd
Publication of GB2034718A publication Critical patent/GB2034718A/en
Application granted granted Critical
Publication of GB2034718B publication Critical patent/GB2034718B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/30Naphthol derivatives, e.g. alpha-naphthyl-esters, i.e. alpha-NE, beta-naphthyl-esters, i.e. beta-NE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • G01N2333/96441Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention provides prolylphenylalanylarginine derivatives represented by the formula <IMAGE> wherein R1 represents hydrogen or benzoyl and R2 represents naphthyl or 6-bromo-2-naphthyl, which are substrates for various enzymes, such as trypsin, plasmin, kallikrein, urokinase and Cl-esterase, and may therefore be used as substrates in the measurement of enzyme activity.

Description

SPECIFICATION Prolylphenylalanylarginine Derivatives Process for their Preparation and their Use for Measuring Enzyme Activity This invention relates to a prolylphenylalanylarginine derivative, a process for producing the same and a method for measuring the activity of enzymes using the compound as a substrate.
Hitherto, many methods have been known for measuring the activity of enzymes. One of them is a method by which an alkyl ester of an amino acid is contacted as a substrate with an enzyme and the activity of the enzyme is determined from the degree of hydrolysis of the alkyl ester. For example, the well-known Hestrin method is one of the methods. This is a method which comprises contacting an enzyme with an alkyl ester of an amino acid, converting the remaining ester group after a given period of time with hydroxylamine into a hydroxamic acid, allowing it to react with ferric chloride to develop a color, and measuring the color as an absorbance, and determining the enzyme's ability to hydrolyze the ester, namely, the activity of enzyme, from the absorbance.
In addition, there is a method in which paranitroanilide of amino acid is used as a substrate and the ability to hydrolyze the same is used as an index, or the like. In these methods, a considerable amount of an enzyme is required, and when the enzyme concentration is low, or when the enzyme has a low activity, it has been difficult to measure the activity of enzyme.
The present inventors have conducted extensive research on compounds satisfying the following three conditions: they have an affinity to an enzyme, the determination of the amount thereof is easy, and the detection sensitivity thereof is good. Consequently, the inventors have found compounds useful as substrate which are very excellent as to the above conditions as compared with the conventional ones, and a simple method for measuring the activity of enzyme by use of the compounds.
An object of this invention is to provide a novel amino acid derivative which is useful as an excellent substrate for an enzyme.
Another object of this invention is to provide a process for producing the said novel amino acid derivative.
A further object of this invention is to provide e method for measuring the activity of an enzyme by using said novel amino acid derivative as a substrate for the enzyme.
Other objects and advantages of this invention will become apparent from the following description.
According to this invention, there is provided a prolylphenylalanylarginine derivative represented by the formula,
wherein R, is hydrogen or benzoyl; and R2 is naphthyl or 6-bromo-2-naphthyl.
This invention further provides a process for producing a prolylphenylalanylarginine derivative represented by the formula (I), which comprises subjecting to dehydration-condensation a compound (II) represented by the formula,
wherein R3 represents benzoyl or an aminoprotecting group, and an arginine derivative (III) represented by the formula,
wherein R2 has the same meaning as defined above and R4 represents an amino-protecting group, in a conventional manner to obtain a compound (IV) represented by the formula,
wherein R2, R3 and R4 have the same meanings as defined above, and then removing the aminoprotecting group from the compound (IV) in a conventional manner.
According to this invention, there is further provided a method for measuring the activity of an enzyme which comprises contacting a prolylphenylalanylarginine derivative represented by the formula (I) as a substrate with the enzyme.
The starting compound (II) used in the production of the compound (I) of this invention may-be any of the compounds stated in Chem.
Pharm. Bull., Vol. 20, pp. 664-668, or may be prepared by condensing a compound (V) represented by the formula,
wherein R3 has the same meaning as defined above, with a compound (VI) represented by the formula,
wherein R5 represents alkyl, into an ester (VII) represented by the formula,
wherein R3 and R5 have the same meanings as defined above, and then hydrolyzing the ester (ill).
The starting arginine derivative (III) includes NG,NG-dibenzyloxycarbonyl-L-arginine 1-naphthyl ester trifluoroacetate, NG,NG-dibenzyloxycarbonyl L-arginine 6-brome-2-naphthyl ester trifluoroacetate, and the like, and may be prepared by naphthylating an arginine derivative (III') having a suitable protecting group represented by the formula,
wherein R4 has the same meaning as defined above, and R4, represents an amino-protecting group different from the R4 group, to form a compound (III") represented the formula,
wherein R2, R4 and R4 have the same meanings as defined above, and then selectively removing only the amino-protecting group in the a-position from the compound (III").
In the production of the compound (IV), the compound (II) and the arginine derivative (III) are dissolved in a suitable solvent, and to the resulting solution is added an activating agent which is usually used, such as dicyclohexylcarbodiimide (DCC), diphenylphosphorylazide (DPPA), an alkyl chlorocarbonate or the like, after which, if necessary, a base such as triethylamine or the like, is added thereto and the resulting mixture is stirred, thereby preparing the compound (IV). The solvent used includes conventional solvents such as chloroform, dichloromethane, dimethylformamide, tetrahydrofuran and the like as far as the starting materials can be dissolved therein. The reaction temperature may be within the range of 0 to 40"C.
After the completion of the reaction, the compound (IV) can be isolated from the reaction mixture by a conventional treatment. That is to say, when DCC is used as the activating agent, the dicyclohexylurea (DCU) precipitated is removed by filtration, and a suitable extracting solvent such as ethyl acetate is added to the filtrate, after which the extract is washed with an aqueous citric acid solution, saturated aqueous sodium bicarbonate solution or saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then evaporated under reduced pressure to remove the solvent to obtain the compound (IV).
The amino-protecting group of the compound (IV) is removed in a conventional manner. That is to say, when the amino-protecting group is benzyloxycarbonyl, the compound (IV) is dissolved in a suitable solvent and a catalyst such as palladium-carbon or the like is added to the resulting solution to remove the protecting group reductively, or the compound (IV) is added to a solution of hydrobromic acid in acetic acid and the hydrobromide of the objective compound precipitated is taken out by filtration, whereby the compound (I) is obtained.
The compound (I) of this invention is useful as an excellent substrate for various enzymes such as trypsin, plasm in, kallikrein, urokinase, CIesterase, thrombin and the like. That is to say, when the compound (I) of this invention is contacted with an enzyme, the compound serves as a substrate, and naphthol or 6-bromo-2naphthol is liberated by hydrolysis with the enzyme after a given period of time, after which the amount of the naphthol or 6-bromo-2naphthol is measured to determine the activity of the enzyme. The fact that the activity of an enzyme can be measured easily is very important for quantitative analysis of an enzyme preparation, diagnosis by measuring the enzyme pattern in blood, diagnosis by measuring the enzyme concentration in blood or urine, or the like.
When the activity of an enzyme is measured according to the method of this invention, the enzyme is contacted with a given amount of the compound (I) of this invention in a suitable buffer solution, and after a given period of time at a given temperature, the amount of naphthol or 6bromo-2-naphthol liberated is measured, thereby determining the activity of the enzyme. The buffer solution may be a suitable one having the optimum pH for the enzyme. The reaction may be effected under suitable constant conditions as to temperature and time, though it is preferable to measure the amount of the naphthol or 6-bromo2-naphthol liberated at a temperature of 250 to 370C after 30 min.
The measurement of the amount of naphthol or 6-bromo-2-naphthol may be conducted by any of the known methods, for example, a physicochemical method, such as, gas chromatography, thin layer chromatography, or the like; or a chemical method, such as, ferric chloride reaction, diazo-coupling reaction. Fast Violet B salt (FVB) method, or the like, though a method which comprises adding FVB to the reaction mixture to develop a color and measuring the absorbance by means of a photometer is more preferable in view of simplicity and detection sensitivity.
When the activity of an enzyme is measured using L-prolyl-L-phenylalanyl-L-arginine 1naphthyl ester as a substrate, the detection sensitivity is higher than when the activity is measured using Ns > -benzoyl-L-arginine ethyl ester or N-tosyl-L-arginine methyl ester (TAME), which has hitherto been known as a substrate for enzymes, according to the Hestrin method, and in particular, the L-prolyl-L-phenylalanyl-Larginine 1-naphthyl ester has a detection sensitivity to kallikrein about 1 60 times that of Na-benzoyl-L-arginine ethyl ester or Natosyl-L-arginine methyl ester, and about 1 5 times that of L-prolyl-L-phenylalanyl-L-arginine Pnitroanilide.
The amount of the naphthol or 6-bromo-2naphthol measured by said method corresponds to the activity or amount of the enzyme.
According to the process of this invention, a change in enzyme concentration in blood or urine due to various diseases can easily be detected.
For example, there is a relationship between essential hypertension and the kallikrein concentration in urine of a hypertensive, and it is said that essential hypertension may be diagnosed by measuring the kallikrein concentration. Hitherto, the following methods for measuring the kallikrein concentration in urine have been known: 1. Assay of TAME (Tohoku J. Med., 116 (1975) by Masahide Seino) 2. Bioassay (Tohoku J. Exp. Med., 87 (1965) by Keishi Abe) 3. Radioimmunoassay.
These are complicated in operation, and the results obtained are greatly fluctuated. In addition, the methods are expensive and often inconvenient for clinical examination. However, when the compound (I) of this invention is used, the kallikrein concentration in urine can be determined from a small amount of urine by a simple operation.
The method for measuring the activity of an enzyme of this invention can be applied to not only a single enzyme-containing system but also a system containing various systems. That is to say, the measurement of the enzyme pattern in urine or blood has been interesting for diagnosis of disease, but conventional methods have not been so often conducted because of their complexities.
However, with this invention, their complexities have been cleared. When, for example, the activity of an enzyme contained in urine is measured, an enzyme pattern in urine which has never been seen has been made possible to see by adding urine on a suitable supporter, separating enzymes therefrom by electrophoresis or the like, immersing the enzymes in an aqueous solution of the compound (I) of this invention for a suitable period of time, and then adding the above-mentioned color developing agent thereto.
This invention is further illustrated below referring to Examples and the accompanying drawings, in which Fig. 1 shows standard curves of the concentration of human urinary kallikrein, Fig. 2 is a graph showing the activity of human urinary kallikrein in human urine, and Fig. 3 shows the enzyme pattern in urine obtained by isoelectrophoresis.
Example 1 Production of L-prolyl-L-phenylalanyl-Larginine 1-naphthyl Ester Dihydrochloride In 5 ml of dimethylformamide (dmf) were disssolved 396 mg of N-benzyloxycarbonyl-Lprolyl-L-phenylalanine and 682 g of NG,NG- dibenzyloxycarbonyl-L-arginine 1 -naphthyl ester trifluoroacetate, and to the resulting solution were added 268 mg of dicyclohexylcarbodiimide (DCC), 135 mg of 1 -hydroxybenzotriazole (HOBt) and 0.14 ml of triethylamine (TEA) with ice-cooling after which the mixture was stirred for 3 hrs at the same temperature. The temperature was elevated to room temperature and the mixture was stirred for a further 24 hrs.The crystals of dicyclohexylurea (DCU) precipitated after the reaction were removed by filtration, and ethyl acetate was added to the filtrate, and the mixture was washed with 10% aqueous citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and thereafter evaporated under reduced pressure to remove the solvent, after which the white powder thus precipitated was collected and recrystallized from chloroform-ether to obtain 600 mg (yield 63%) of N-benzyloxyca rbonyl-L-prolyl-L-phenyla lanyl NG,NG-dibenzyloxycarbonyl-L-arginine 1 -naphthyl ester, M.P. 164-1 670C.
IR vmKBaxcml:3300,2925, 1745, 1710, 1630.
NMR a ppm (DMSO-d6): 1.5-2.2 (8H, broad), 3.0 (2H, m), 4.0--4.4 (4H, broad), 4.7 (2H, broad), 4.9 (2H, broad), 5.1 (2Hx2, s), 5.3 (2H, s), 7.0-8.4 (aromatic protons).
In 10 ml of DMF was dissolved 500 mg of the above ester, and to the resulting solution were added 200 mg of 10% palladium-carbon (Pd-C) and 1.0 g of a hydrochloric acid-dioxane solution (110 mg HCI/g), after which the resulting mixture was stirred at room temperature for 2 hrs while passing hydrogen gas therethrough. After the reaction, the Pd-C was removed by filtration, and 40 ml of anhydrous diethyl ether was added to the filtrate, upon which an oily substance was precipitated. The supernatant was removed by decantation, and 40 ml of anhydrous diethyl ether was added again to the residue and the mixture was stirred to obtain 200 mg (yield 61%) of white powder of L-prolyl-L-phenylalanyl-L-arginine 1 naphthyl ester dihydrochloride, m.p. 87-900C (decomp.).
IR vmKBacml:3350, 1750,1650.
The NG,NG-dibenzyloxycarbonyl-L-arginine-1- naphthyl ester trifluoroacetate used as the starting material was prepared as follows: In 30 ml of anhydrous pyridine was dissolved 9.1 g of N(x-4-methoxybenzyloxycarbonyl-NG,NG- dibenzyloxycarbonyl-L-arginine (Z Natu rf. 20b, 429 (1965), F. Weygand, E. Nintz), and 7.9 g of 1,1 '-dinaphthyl sulfite was added to the solution.
The resulting mixture was stirred at room temperature for 24 hrs. Ethyl acetate was added to the reaction mixture, and the mixture was washed with 10% citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution in this order, dried over anhydrous magnesium sulfate, and then evaporated under reduced pressure to dryness.
Anhydrous diethyl ether was added to the residue to wash the latter, thereby obtaining 9.0 g (yield 82%) of a pale yellow, viscous, oily substance, which was Na-4-methoxybenzyloxycarbonyl- NG,NG-dibenzyloxycarbonyl-L-arginine 1-naphthyl ester.
IR p KBr cm~1: 3400, 1760, 1720, 1690.
NMR a ppm (CDCl3 1.9 (4H,m), 3.7 (3H,s), 4.1 (2H,M), 4.8 (1 H, m), 5.1 (2Hx2, s), 5.2 (2H, s), 6.7--8.0 (aromatic protons).
To 8.0 g of the above ester was added 1 5 ml of trifluoroacetic acid, and the mixture was stirred with ice-cooling for 30 min. After the reaction, the trifluoroacetic acid was removed by evaporation under reduced pressure, and anhydrous diethyl ether was added to the residue to dissolve the latter, after which the resulting solution was allowed to stand. The colorless needle crystals thus precipitated were collected to obtain 4.5 g (yield 61%) of NG,NG-dibenzyloxycarbonyl-L- arginine 1-naphthyl ester trifluoroacetate, m.p.
149-151 0C.
IR vcm1: 3400, 1760, 1720, 1 660.
MMR 8 ppm (CDCl3+DMSO-d6): 2.1 (4H, m), 4.0 (2H, m), 4.5 (1 H, m), 5.1 (2H, s), 5.2 (2H, s), 7.1--8.0 (aromatic protons).
Example 2 Production of Benzoyl-L-prolyl-L-phenylalanyl L-arginine 1-Naphthyl Ester Hydrochloride In 10 ml of DMF were dissolved 752 mg of benzoyl-L-prolyl-L-phenylalanine and 1.364 g of NG,NG-dibenzyloxycarbonyl-L-argin ìne 1 -naphthyl ester trifluoroacetate, after which 535 mg of DCC, 270 mg of HOBt and 0.28 ml of TEA were added to the resulting solution with ice-cooling and stirred for 3 hrs. The temperature thereof was thereafter elevated to room temperature, and the mixture was stirred for a futher 24 hrs at room temperature.After the reaction, the DCU thus precipitated was removed by filtration, and ethyl acetate was added to the filtrate, and the resulting mixture was washed with 10% citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution in this order, dried over anhydrous magnesium sulfate and then evaporated under reduced pressure to remove the solvent. The residue was recrystallized from ethyl acetate-diethyl ether-nhexane to obtain 1.20 g (yield 62%) of white powder, m.p. 1 40--143 C, which was benzoyl L-prolyl-L-phenylalanyl-NG,NG dibenzyloxycarbonyl-L-arginine 1 -naphthyl ester.
IR VmBax cm-t: 3400, 3300, 1750, 1720, 1640, 1610.
NMR 8 ppm (CDCl3): 1.6-2.2 (8H, broad), 3.2 (2H, m), 3.5 (2H, m), 4.0 (2H, m), 4.4-5.0 (3H, m), 5.2 (2H, s), 5.3 (2H, s), 7.0--8.0 (aromatic protons).
In 10 ml of DMF was dissolved 962 mg of the above ester, after which 500 mg of 10% Pd-C and 0.5 ml of hydrochloric acid-dioxane solution (98 mg HCI/g) were added to the resulting solution.
The resulting mixture was stirred at room temperature for 3 hrs while passing hydrogen gas therethrough. After the reaction, the Pd-C was removed by filtration, and 100 ml of anhydrous diethyl ether was added to the filtrate, upon which an oily substance was precipitated. The supernatant was removed by decantation, and anhydrous diethyl ether was added again to the residue, and the mixture was stirred to obtain 600 mg (yield 87%) of white powder, m.p. 80-900C (decomp.), which was benzoyl-L-prolyl-L- phenylalanyl-L-arginine 1-naphthyl ester hydrochloride.
jlR p KBr CIT1 1: 3600,1750,1650.
The benzoyl-L-prolyl-L-phenylalanine used as the starting material was prepared in the following manner: In 100 ml of dichloromethane were dissolved 10.7 g of benzoyl-L-proline and 11.5 g of Lphenylalanine ethyl ester hydrochloride, and 1 5.3 g of DPPA and 15 ml of TEA were added thereto with ice-cooling, after which the mixture was stirred for 24 hrs. The reaction mixture was washed with 10% citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution in this order, then dried over anhydrous magnesium sulfate, and thereafter evaporated under reduced pressure to remove the solvent. The residue was recrystallized from ethyl acetate to obtain 1.20 g (yield 62%) of white powder, m.p. 133--135 C, which was benzoyl-L-prolyl-L-phenylalanine ethyl ester.
In 100 ml of methanol was dissolved 12.0 g of the above ester, and 45 ml of 1 N sodium hydroxide solution, after which the mixture was stirred for 5 hrs. The methanol was removed at a low temperature, and ethyl acetate and distilled water were then added to the residue, after which the resulting mixture was shaken. The aqueous layer was weakly acidified with 10% aqueous hydrochloric acid solution, and the crystalline powder thus precipitated was collected to obtain 10.6 g (yield 95%) of benzoyl-L-prolyl-Lphenylalanine, m.p. 200-2020C.
IR vmKBaxcml:3375, 1730,1670.
Example 3 Production of Benzoyl-L-prolyl-L-phenylalanyl L-arginine 6-bromo-2-naphthyl Ester Hydrochloride In 10 ml of DMF were dissolved 376 mg of benzoyl-L-prolyl-L-phenylalanine and 761 mg of NG,NG-dibenzyloxycarbonyl-L-arginine 6-bromo2-naphthyl ester trifluoroacetate, after which 267 mg of DCC,135 mg of HOBt and 0.17 ml of TEA were added thereto with ice-cooling, and the mixture was stirred for 3 hrs, and then at room temperature for a further 24 hrs. The DCU thus precipitated was removed by filtration, and ethyl acetate was added to the filtrate, after which the mixture was washed with 10% citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution in this order, and then dried over anhydrous magnesium sulfate.The solvent was removed by evaporation under reduced pressure, and the residue was recrystallized from ethyl acetate-diethyl ether to obtain 500 mg (yield 50%) of white powder, m.p.
94-970C, which was benzoyl-L-prolyl-L phenyla lanyl-NG,NG-dibenzyloxycarbonyl-L- ginine 6-bromo-2-naphthyl ester.
IRvmKBaxcml:3375, 1750,1710,1610.
In 5 ml of DMF was dissolved 0.5 g of the above ester, after which 250 mg of 10% Pd-C, and 250 mg of hydrochloric acid-dioxane solution (98 mg HCI/g) were added thereto. The mixture was stirred at room temperature for 3 hrs while passing hydrogen gas therethrough. After the reaction, the reaction mixture was filtered to remove Pd-C, and 100 ml of anhydrous diethyl ether was added to the filtrate. The white powder thus precipitated was collected to obtain 210 mg (yield 38%) of benzoyl-L-prolyl-L-phenylalanyl-Larginine 6-bromo-2-naphthyl ester hydrochloride, m.p. 80--850C.
IR VmKBaxr cm :3350,1750,1650.
Example 4 Production of L-ProIyl-Lphenytalanyl-L arginine 6-Bromo-2-naphthyl Ester Dihydrochloride In 10 ml of DMF were dissolved 396 mg of Nbenzyloxycarbonyl-L-prolyl-L-phenylaranine and 761 mg of NO,NG-dibenzyloxyca rbonyl-Larginine 6-bromo-2-naphthyl ester trifluoroacerate, after which 267 mg of DCC, 135 mg of HOBt and 0.17 ml of TEA were added thereto with ice-cooling.
The mixture was stirred for 3 hrs with ice-cooling and then at room temperature for 24 hrs. The DCU thus precipitated was removed by filtration, and ethyl ester was added to the filtrate. The resulting mixture was washed with 10% citric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution in this order, dried over anhydrous magnesium sulfate and then evaporated under reduced pressure to remove the solvent. Diethyl ether was added to the residue, and the resulting mixture was stirred to obtain 610 mg (yield 59.5%) of white powder, m.p. 125-1 3O0C, which was Nbenzyloxyca rbonyl-L-prolyl-L-phenylala nyl-NG,NG- dibenzyloxycarbonyl-L-arginine 6-bromo-2naphthyl ester.
IR ImKBaxrcml:3400,3300, 1750,1710,1650, 1610.
NMR 6 ppm (CDC13): 1.5-2.2 (8H, broad), 3.1 (2H, m), 3.4 (2H, m), 4.0 (3H, m), 4.7, (2H, m), 5.1 (2H, s), 5.2 (2H, s), 5.3 (2H, s), 7.1- 8.0 (aromatic protons).
In 5 ml of DMF was dissolved 510 mg of the above ester, after which 250 mg of 10% Pd-C and 440 mg of hydrochloric acid-dioxane solution (98 mg HCI/g) were added thereto, and the mixture was stirred at room temperature for 3 hrs while passing hydrogen gas therethrough. After the reaction, the Pd-C was removed by filtration, and 100 ml of anhydrous diethyl ether was added to the filtrate, and the mixture was allowed to stand with ice-cooling for 24 hrs. The supernatant was removed by decantation, and diethyl ether was again added to the residue, and the mixture was stirred to obtain 230 mg (yield 67%) of white powder, m.p. 80--840C, which was L-prolyl-Lphenylalanyl-L-arginine 6-bromo-2-naphthyl ester dihydrochloride.
IR vmKxcml:3350, 1750, 1655.
Example 5 Measurement of the Activity of Kallikrein by use of L-Prolyl-L-phenylalanyl-L-arginine 1 Naphthyl Ester Dihydrochloride as Substrate To 1.7 ml of 50 mM phosphate buffer solution (pH 7.0) were added 0.1 ml of human urinary kallikrein at various concentrations, and 0.2 ml of 1.5 mM solution of L-prolylphenyl-L-alanyl-Larginine 1-naphthyl ester dihydrochloride dissolved in 0.15% of sodium laurylsulfate solution, after which the mixture was subjected to incubation at 370C for 30 min. To the mixture was added 20 microliters of 8% sodium laurylsulfate solution and the resulting mixture was cooled with iced water. To the mixture was added 0.2 ml of 1% FVB solution, and the mixture was allowed to stand at O"C for 10 min, after which 2 ml of glacial acetic acid was added.The color thus developed was measured as absorbance (505 nm) by means of a spectrophotometer to determine the amount of the naphthol liberated. As a control, the buffer solution free from kallikrein was used. The amount of the naphthol liberated corresponded to the activity of the enzyme.
The results obtained at each kallikrein concentration by the above method are shown in Fig. 1.
When benzoyl-L-prolyl-L-phenylalanyl-L- arginine 1-naphthyl ester hydrochloride was used, the absorbance was measured at 505 nm, and when 6-bromo-2-naphthyl ester was used the absorbance was measured at 530 nm.
Comparative Example 1 Measurement of the Activity of Kallikrein by use of Na-Tosyl-L-arginine Methyl Ester Hydrochloride as Substrate To 0.5 ml of urinary kallikrein were added 0.4 ml of N-tosylarginine methyl ester solution (10 micromoles/0.4 ml of 5% DMSO) and 0.1 ml of phosphate buffer (pH 7.4). The mixture was subjected to incubation at 370C for 30 min, and 1.5 ml of hydroxylamine solution (a mixture of equal amounts of 2 M NH2OH hydrochloride and 3.5 M NaOH) was added thereto, after which the mixture was allowed to stand at room temperature for 1 5 min. Thereto were added 1 ml of 18% trichloroacetic acid solution, 1 ml of 4 N hydrochloric acid and 1 ml of 10% ferric chloride solution, and the resulting mixture was stirred thoroughly and then centrifuged at 3,000 r.p.m.
for 10 min. The color developed in the supernatant was measured as absorbance (530 nm) by means of a spectrophotometer. The value obtained corresponds to the amount of the substrate remaining unhydrolyzed with kallikrein, and therefore, the activity of the enzyme corresponds to the difference between the value obtained when no enzyme was used (control) and the value obtained after the enzyme reaction.
The results obtained at each kallikrein concentrations in Example 5 and Comparative Example 1 are shown in Fig. 1, from which it can be seen that the method in Example 5 has a sensitivity about 1 60 times that in the method in Comparative Example 1. In Fig. 1, curve A indicates the standard curve obtained by the method of Example 5 using L-prolyl-Lphenylalanyl-L-arginine 1-naphthyl ester dihydrochloride as a substrate, and curve B indicates the standard curve obtained by the method of Comparative Example 1, in which the numbers in parentheses should be used as the unit of abscissa.
Example 6 Measurement of Kallikrein in Human Urine To 0.1 ml of human urine were added 1.7 ml of 50 mM phosphate buffer solution (pH 7.0) and 0.2 ml of 1.5 mM L-prolyl-L-phenylalanyl-Larginine 1-naphthyl ester dihydrochloride solution, and the mixture was subjected to incubation at 370C for 30 min. The mixture was cooled to OOC, and 0.2 ml of 1% FVB solution was added thereto, and the resulting mixture was allowed to stand at OOC for 10 min, after which 2 ml of glacial acetic acid was added thereto and the color thus developed was measured as absorbance (505 nm) by means of a spectrophotometer, thereby determining the amount of naphthol liberated by hydrolysis with the enzyme.As a control, the same procedure as above was repeated, except that the human urine was used after heat-treated, to measure absorbance, and the difference in absorbance (AA) between the two cases was obtained. This difference corresponds to the amount of the kallikrein in human urine. The results of the measurement by the above method are shown in Fig. 2, in which urine samples were obtained from 8 different men (Sample Nos. 1 to 8).
Example 7 Measurement of Enzyme Pattern in Urine by Isoelectrophoresis A 4% acrylamide gel column containing 2% Ampholine Q (pH 3.5-5) at a final concentration was prepared by use of a glass tube of 9 mm in inner diameter and 10 cm in length.
2.5 ml of urine was freeze-dried and dissolved in 50 microliters of water to prepare a test specimen. This test specimen was added to the above column and subjected to electrophoresis at 200V for 4 hrs, after which the gel was taken out, washed with water, immersed in 0.5 M phosphate buffer solution for 5 min, then immersed in 0.25 M phosphate buffer solution (pH 7.0) containing 0.2 micromole of L-prolyl-Lphenylalanyl-L-arginine 1 -naphthyl ester and 1 % FVB, and thereafter subjected to incubation at 370C for 30 min. By the above method, the enzyme pattern in urine can be observed as a pink or violet band. Fig. 3 shows the enzyme pattern obtained when a normal human urine was used.

Claims (1)

  1. Claims
    1. A prolylphenylalanylarginine derivative represented by the formula.
    wherein R, represents hydrogen or benzoyl; and R2 represents naphthyl or 6-bromo-2-naphthyl.
    Ol-prolyl-L-phenylalanyl-L-arginine 1naphthyl ester.
    3. Benzoyl-L-prolyl-L-phenylalanyl-L-arginine 1 -naphthyl ester.
    4. L-prolyl-L-phenylalanyl-L-arginine 6-bromo2-naphthyl ester.
    5. Benzoyl-L-prolyl-L-phenylalanyl-L-arginine 6-bromo-2-naphthyl ester.
    6. A process for producing a prolylphenylalanyl-arginine derivative represented by the formula,
    wherein R, represents hydrogen or benzoyl and R2 represent naphthyl or 6-bromo-2-naphthyl, which comprises subjecting to dehydrationcondensation a compound (II) represented by the formula,
    wherein R3 represents benzoyl or an aminoprotecting group, and an arginine derivative (III) represented by the formula,
    wherein R2 has the same meaning as defined above and R4 represents an amino-protecting group in a conventional manner to obtain a compound (IV) represented by the formula,
    wherein R2, R3 and R4 have the same meanings as defined above, and then removing the aminoprotecting group from the compound (IV) in a conventional manner.
    7. A process according to Claim 6, wherein the dehydration-condensation reaction is effected at a temperature of 0 to 400C in a solvent.
    8. A method for measuring the activity of an enzyme, which comprises contacting the enzyme with a prolylphenylalanylarginine derivative represented by the formula,
    wherein R, represents hydrogen or benzoyl and R2 represents naphthyl or 6-bromo-2-naphthyl, as a substrate.
    9. A process according to Claim 8, wherein the enzyme is contacted with the prolylphenylalanylarginine derivative (I) for a given period of time, and thereafter, the amount of the naphthol or 6-bromo-2-naphthol liberated by the hydrolysis with the enzyme is measured.
    10. A process according to Claim 9, wherein the enzyme is kallikrein.
GB7937424A 1978-10-30 1979-10-29 Prolyl-phenylalanylarginine derivatives process for their preparation and their use for measuring enzyme activity Expired GB2034718B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13339378A JPS5827784B2 (en) 1978-10-30 1978-10-30 amino acid derivative

Publications (2)

Publication Number Publication Date
GB2034718A true GB2034718A (en) 1980-06-11
GB2034718B GB2034718B (en) 1983-01-06

Family

ID=15103689

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7937424A Expired GB2034718B (en) 1978-10-30 1979-10-29 Prolyl-phenylalanylarginine derivatives process for their preparation and their use for measuring enzyme activity

Country Status (4)

Country Link
JP (1) JPS5827784B2 (en)
DE (1) DE2943582C2 (en)
FR (1) FR2440356A1 (en)
GB (1) GB2034718B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044127A1 (en) * 1980-07-10 1982-01-20 The Regents Of The University Of California Test kit to identify potential contrast media reactors
EP0167980A2 (en) * 1984-07-04 1986-01-15 Nitto Boseki Co., Ltd. Novel substrates for use in measuring the concentration of kallikrein in urine
CN114184562A (en) * 2021-11-19 2022-03-15 北京赛升药业股份有限公司 Method for determining urokinase activity by chromogenic substrate method

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386075A (en) * 1982-02-17 1983-05-31 Smithkline Beckman Corporation Renally active tetrapeptides
US4387049A (en) * 1982-02-22 1983-06-07 Smithkline Beckman Corporation Adamantyl containing peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2527932C2 (en) * 1974-07-02 1983-04-21 Pentapharm AG, 4052 Basel Acid addition salts of tripeptide derivatives and their use as substrates for the determination of plasma kallikrein

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044127A1 (en) * 1980-07-10 1982-01-20 The Regents Of The University Of California Test kit to identify potential contrast media reactors
EP0167980A2 (en) * 1984-07-04 1986-01-15 Nitto Boseki Co., Ltd. Novel substrates for use in measuring the concentration of kallikrein in urine
EP0167980A3 (en) * 1984-07-04 1988-10-26 Nitto Boseki Co., Ltd. Novel substrates for use in measuring the concentration of kallikrein in urine
CN114184562A (en) * 2021-11-19 2022-03-15 北京赛升药业股份有限公司 Method for determining urokinase activity by chromogenic substrate method

Also Published As

Publication number Publication date
DE2943582A1 (en) 1980-05-29
GB2034718B (en) 1983-01-06
DE2943582C2 (en) 1982-11-18
FR2440356B1 (en) 1983-11-25
JPS5827784B2 (en) 1983-06-11
FR2440356A1 (en) 1980-05-30
JPS5559151A (en) 1980-05-02

Similar Documents

Publication Publication Date Title
US4278763A (en) Diagnostic agents for the detection of proteolytic enzymes
US4717658A (en) Gram negative bacteria screening method with horseshoe crab amebocyte lysate (LAL)
US4657855A (en) Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample
PL90746B1 (en)
NO164201B (en) REAGENT FOR SPECTROPHOTOMETRIC DETERMINATION OF THE EXISTENCE OF LEUKOCYTES, ESTERASE OR PROTEASE IN A SAMPLE, PROCEDURES INCLUDING THIS AND PROCEDURE FOR DETERMINING THE CONDUCT.
US4645842A (en) Pyrrole compounds for detecting the presence of hydrolytic analytes
US4308202A (en) Prolylphenylalanylarginine derivatives, process for producing same and method for measuring activity of enzymes using same
US4209459A (en) Novel L-leucyl-4-hydroxyanilide derivatives
US4379764A (en) Phenylalanylarginine derivatives, process for producing same and method for measuring activity of enzymes using same
US4257940A (en) Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same
GB2034718A (en) Prolylphenylalanylarginine Derivatives, Process for Their Preparation and Their Use for Measuring Enzyme Activity
US4308201A (en) Phenylalanylvalylarginine derivative, process for producing same and method for measuring activity of enzymes using same
US4505852A (en) 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors
US6503725B2 (en) Composition and device for detecting leukocytes in urine
US4418012A (en) Leucylalany-arginine derivative
US4292404A (en) Method for determining the activity of the angiotensin-converting enzyme
US6528652B1 (en) Composition and device for detecting leukocytes in urine
JP2660864B2 (en) Aminoacetophenone derivatives and methods for measuring enzyme activity using the same
JPS5850986B2 (en) Lysine derivative
JPS6029702B2 (en) arginine derivative
JPS6342638B2 (en)
JPS5925363A (en) Tyrosine derivative
WO2000043535A2 (en) Composition and device for detecting leukocytes in urine
JPH01221395A (en) Polypeptide derivative

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19941029